Leflunomide availability in 2026: a clinical perspective for providers

If your patients have been reporting difficulty filling their Leflunomide prescriptions, you're likely hearing a real and increasingly common frustration. While Leflunomide is not in a formal FDA-listed critical shortage as of early 2026, intermittent supply disruptions have made it harder for patients to access this important DMARD consistently.

This article provides an evidence-based overview of the current Leflunomide supply situation, the factors driving availability issues, clinical considerations for managing patients during supply gaps, and practical tools you can recommend to help patients locate their medication.

Current supply status

Leflunomide (generic for Arava) currently has a findability score of 72 out of 100, indicating that it is generally available but subject to minor supply fluctuations. Key points:

• The 20 mg tablet — the most commonly prescribed strength — has been more affected by supply inconsistencies than the 10 mg tablet.
• Supply disruptions are intermittent and regional rather than sustained and nationwide.
• Multiple generic manufacturers (Teva, Apotex, Sandoz, Aurobindo, and others) produce Leflunomide, but individual manufacturer supply interruptions can create localized shortages.
• Distributor allocation practices may limit pharmacy access, particularly for pharmacies with low historical ordering volume for this medication.

What's driving the supply disruptions?

Several interconnected factors contribute to the inconsistent availability of generic Leflunomide:

Concentrated generic manufacturer base

Despite being off-patent for over a decade, Leflunomide's generic market is served by a relatively small number of manufacturers. This concentration means that production issues at even one facility — whether due to FDA inspection findings (Form 483s), equipment downtime, or quality assurance holds — can disproportionately affect overall supply.

API sourcing vulnerabilities

The active pharmaceutical ingredient for Leflunomide is primarily manufactured at overseas facilities. Global supply chain disruptions, including shipping delays, regulatory changes in API-exporting countries, and quality audit failures at API manufacturers, create upstream bottlenecks that delay finished dosage form production.

Demand dynamics

Leflunomide remains a cornerstone conventional DMARD for rheumatoid arthritis, particularly for:

• Patients who are intolerant of or contraindicated for Methotrexate
• Patients who require an alternative or additional conventional DMARD before stepping up to biologic therapy
• Patients transitioning from biologic DMARDs due to cost, insurance changes, or adverse effects

As biologic and JAK inhibitor costs remain high (even with biosimilar competition), some patients and payers are favoring conventional DMARDs like Leflunomide, maintaining steady demand against a constrained supply.

Distributor allocation algorithms

Wholesale distributors use algorithmic allocation based on historical ordering patterns. During supply-constrained periods, pharmacies that haven't consistently stocked Leflunomide may receive reduced allocations — creating a feedback loop where patients at those pharmacies face disproportionate difficulty.

Clinical considerations during supply disruptions

Continuity of therapy

Leflunomide's active metabolite, teriflunomide (A77 1726), has an exceptionally long elimination half-life of approximately 14-18 days. Without a cholestyramine or activated charcoal washout procedure, teriflunomide can remain detectable in plasma for up to 2 years after discontinuation.

This pharmacokinetic profile provides a clinical buffer: a brief gap in Leflunomide supply (days to a few weeks) is unlikely to result in complete loss of therapeutic drug levels. However, this should not be used as a rationale for indefinite treatment interruption, as subtherapeutic levels will eventually be reached, increasing the risk of disease flare.

Switching considerations

If a patient cannot access Leflunomide for an extended period, the following alternatives may be appropriate depending on the clinical scenario:

• Methotrexate: First-line DMARD for RA. If transitioning from Leflunomide, consider a cholestyramine washout (8g TID × 11 days) to reduce hepatotoxicity risk from overlapping drug exposure, per ACR guidelines.
• Sulfasalazine: Appropriate as monotherapy or as part of triple DMARD therapy. Generally well tolerated with gradual dose titration.
• Hydroxychloroquine: Milder DMARD, most appropriate for early or mild disease, or as an adjunct. Unlikely to be sufficient as sole replacement for Leflunomide in moderate-to-severe RA.
• JAK inhibitors (Tofacitinib, Baricitinib, Upadacitinib): Oral targeted therapy option for patients who have failed conventional DMARDs. Note FDA boxed warnings regarding cardiovascular risk, malignancy, and thrombosis. Require prior authorization from most payers.

For a patient-facing overview of alternatives, you can share our guide: Alternatives to Leflunomide.

Monitoring during transitions

When transitioning patients off Leflunomide:

• Obtain baseline LFTs and CBC before starting an alternative DMARD
• If initiating Methotrexate, verify teriflunomide levels are below 0.02 mg/L on two separate tests ≥14 days apart (if performing washout), or monitor LFTs closely if overlapping is clinically necessary
• Schedule follow-up within 4-6 weeks to assess disease activity and medication tolerance
• Document the reason for the switch (supply disruption vs. clinical indication) for insurance and prior authorization purposes

Tools and resources for your patients

Medfinder for providers

Medfinder offers a provider-facing platform that enables your team to help patients locate Leflunomide in stock at pharmacies in their area. Rather than relying on patients to make multiple phone calls, you can direct them to medfinder.com for real-time availability information.

Consider integrating Medfinder as a recommended resource in your practice's patient handouts or EHR-linked materials for patients on medications with known supply variability.

Pharmacy coordination

Encourage your patients to:

• Establish a relationship with an independent or specialty pharmacy that regularly stocks DMARDs
• Request refills 7-10 days before running out to allow time for sourcing
• Consider mail-order pharmacy options through their insurance plan for more consistent access

Patient assistance and cost resources

For patients where cost is an additional barrier:

• Prescription discount cards (GoodRx, SingleCare, RxSaver) can reduce generic Leflunomide to $15-$45/month
• Patient assistance programs through NeedyMeds and RxAssist may help uninsured or underinsured patients
• Sanofi's Patient Connection program may assist with brand-name Arava for qualifying patients

Share our patient guide: How to save money on Leflunomide.

Communicating with patients about supply issues

Patients who can't find their medication often feel anxious and unheard. A few communication strategies can help:

• Validate the experience: Acknowledge that supply disruptions are real and not the patient's fault.
• Provide a plan: Outline specific steps — check Medfinder, try independent pharmacies, call your office if they can't find it within X days.
• Reassure on pharmacokinetics: Explain that Leflunomide's long half-life means a brief gap won't immediately compromise their treatment, while emphasizing the importance of refilling as soon as possible.
• Document proactively: Note supply-related treatment changes in the chart to support future prior authorizations and continuity of care.

Looking ahead

While there is no single fix for generic drug supply variability, several trends may improve Leflunomide access over time:

• Increased FDA attention to drug shortage prevention and manufacturer transparency
• Growth in domestic API manufacturing capacity
• Broader adoption of real-time inventory tools like Medfinder that help match supply with demand more efficiently

In the meantime, proactive management — early refill coordination, pharmacy flexibility, and clear patient communication — remains the most effective strategy for minimizing the impact of Leflunomide supply disruptions on your patients' care.

Provider resources

Visit medfinder.com/providers to learn how Medfinder can support your practice in helping patients access hard-to-find medications.

Related clinical reading: How to help your patients find Leflunomide in stock | Help patients save money on Leflunomide | Leflunomide drug interactions